We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

THE BINDING SITE

Engages in the research, development, manufacture, and distribution of immunodiagnostic assays, as wel as specialized... read more Featured Products: More products

Download Mobile App





Binding Site Showcases Optilite System for Special Protein Testing

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: Optilite special protein analyzer on display at EuroMedLab Rome 2023 (Photo courtesy of Binding Site)
Image: Optilite special protein analyzer on display at EuroMedLab Rome 2023 (Photo courtesy of Binding Site)

Binding Site (Birmingham, UK) is showcasing its Optilite system, the leading solution for multiple myeloma and immune status testing, at the 2023 EuroMedLab Congress.

Optilite represents a significant breakthrough in special protein testing. The innovative system has been fully optimized to simplify complex analytical processes, delivering unparalleled efficiency, workflow optimization, and confidence in test results. With an array of intelligent features, Optilite sets a new standard in the protein laboratory field by seamlessly integrating cutting-edge technology and advanced software.

At EuroMedLab Rome 2023, Binding Site is also presenting its range of in vitro assays, which have received the CE mark for Europe, FDA clearance for the USA, and approval from regulatory authorities in multiple countries. These comprehensive assays cover all five isotypes of immunoglobulins, offering a complete solution. Among the assays being highlighted by Binding Site at the industry event are Freelite and Hevylite, which provide a comprehensive monitoring solution for managing patients with multiple myeloma.

The Freelite assay has significantly enhanced laboratory and clinical practices in the detection and follow-up of monoclonal gammopathies. The Optilite Freelite assay, FDA-cleared for aiding in the diagnosis and monitoring of multiple myeloma, represents the state-of-the-art in free light chain testing. Additionally, Hevylite is a unique immunoassay panel designed to accurately identify and quantify immunoglobulin heavy and light chain isotypes. Together, these advancements by Binding Site contribute to the advancement of diagnostic and monitoring capabilities in the field of multiple myeloma.

Related Links:
Binding Site 

New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test
New
Auto-Chemistry Analyzer
CS-1200

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.